<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577640</url>
  </required_header>
  <id_info>
    <org_study_id>2014H0226</org_study_id>
    <nct_id>NCT02577640</nct_id>
  </id_info>
  <brief_title>Dietary Soy Isoflavones In Chronic Pancreatitis</brief_title>
  <official_title>Dietary Soy Isoflavones In Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dietary Soy Isoflavones in Chronic Pancreatitis: Investigating the Anti-inflammatory Effects&#xD;
      of Food Innovation Science on Gastrointestinal Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Management of pancreatic disorders imparts a major burden on healthcare costs, estimated at&#xD;
      over 3 billion dollars annually. Chronic pancreatitis is characterized by chronic&#xD;
      inflammation and progressive scarring, leading to abdominal pain, irreversible damage to the&#xD;
      pancreas and the loss of both exocrine and endocrine function. Additionally, chronic&#xD;
      pancreatic inflammation is a risk factor for pancreas cancer. There are no current treatments&#xD;
      to modify the natural history of this disorder. Thus, identifying novel therapeutic options&#xD;
      for this disease represents a high priority, and could fill an unmet medical need to improve&#xD;
      quality of life, reduce risk of malignant transformation, and limit exorbitant medical costs&#xD;
      associated with patient care. The investigators have assembled a multi-disciplinary research&#xD;
      team to pursue an alternative, non-pharmacologic approach to limiting inflammatory cascades&#xD;
      in (Chronic Pancreatitis) CP patients. They will assess compliance, toxicity and measure the&#xD;
      changes in pro-inflammatory cytokine expression from a soy based dietary bread product using&#xD;
      a classic 3+3 dose escalation study design in subjects with chronic pancreatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities</measure>
    <time_frame>1 (dose escalation groups) or 4 (maximally tolerated dose) weeks</time_frame>
    <description>Participants were evaluated for the development of bothersome symptoms that prevented them from being able to complete the recommended intervention course. Counts represent number of subjects who developed a symptom that prevented the ability to complete the dose/study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory Cytokines</measure>
    <time_frame>1 (dose escalation group) or 4 weeks (maximally tolerated subject)</time_frame>
    <description>Changes in the serum were assessed for TNF-alpha prior to and following introduction of soy bread</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (DE) Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in &gt;33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maximum Tolerated Dose (MTD) Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy bread</intervention_name>
    <description>Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.</description>
    <arm_group_label>Dose Escalation (DE) Phase</arm_group_label>
    <arm_group_label>Maximum Tolerated Dose (MTD) Phase</arm_group_label>
    <other_name>Soy Isoflavones</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of chronic pancreatitis by fulfilling one of the following clinical&#xD;
             scenarios:&#xD;
&#xD;
               1. Presence of pancreatic calcifications&#xD;
&#xD;
               2. Suggestive for chronic pancreatitis - consistent EUS criteria or at least 3&#xD;
                  abnormal side branches on pancreatic duct imaging&#xD;
&#xD;
               3. Indeterminate EUS findings for chronic pancreatitis with evidence of exocrine&#xD;
                  pancreatic insufficiency (EPI)&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide written consent&#xD;
&#xD;
          2. Inability to comply with the study protocol&#xD;
&#xD;
          3. Soy allergy&#xD;
&#xD;
          4. Pancreatic cancer&#xD;
&#xD;
          5. History of prior pancreatic surgery (this does not include endoscopic therapies)&#xD;
&#xD;
          6. Comorbid diseases characterized by a chronic inflammatory state, including, but not&#xD;
             limited to rheumatologic diseases, chronic kidney disease, extra-pancreatic malignancy&#xD;
&#xD;
          7. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Hart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State Wexner Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philip Hart</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahn-Jarvis J, Lombardo E, Cruz-Monserrate Z, Badi N, Crowe O, Kaul S, Komar H, Krishna SG, Lesinski GB, Mace TA, Ramsey ML, Roberts K, Stinehart K, Traczek M, Conwell DL, Vodovotz Y, Hart PA. Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study. Pancreatology. 2020 Jul;20(5):852-859. doi: 10.1016/j.pan.2020.04.018. Epub 2020 Jun 6.</citation>
    <PMID>32595109</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <results_first_submitted>March 2, 2021</results_first_submitted>
  <results_first_submitted_qc>October 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2021</results_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Philip Hart</investigator_full_name>
    <investigator_title>Assistant Professor-Clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02577640/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Escalation Group 1</title>
          <description>DE group at 1 slice of bread per day.</description>
        </group>
        <group group_id="P2">
          <title>Dose Escalation Group 2</title>
          <description>DE group at 2 slices of bread per day</description>
        </group>
        <group group_id="P3">
          <title>Dose Escalation Group 3</title>
          <description>DE group at 3 slices of bread per day</description>
        </group>
        <group group_id="P4">
          <title>Maximally Tolerated Dose</title>
          <description>maximally tolerated dose of bread for 4 week period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Escalation Group 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dose Escalation Group 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dose Escalation Group 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Maximally Tolerated Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 8 unique subjects were enrolled into the DE phase. One subject was a screen failure due to pre-existing solid food dysphagia, which was not reported at screening. For each of the three doses, three subjects completed all study activities; two subjects completed both dose escalation group 1 and 3.&#xD;
One additional unique subject completed the MTD phases consuming 3 slices per day for 4 weeks.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Escalation Group 1</title>
          <description>1 slice bread per day for 1 week</description>
        </group>
        <group group_id="B2">
          <title>Dose Escalation Group 2</title>
          <description>2 slices bread per day for 1 week</description>
        </group>
        <group group_id="B3">
          <title>Dose Escalation Group 3</title>
          <description>3 slices bread per day for 1 week</description>
        </group>
        <group group_id="B4">
          <title>Maximally Tolerated Dose</title>
          <description>maximally tolerated dose for 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose Limiting Toxicities</title>
        <description>Participants were evaluated for the development of bothersome symptoms that prevented them from being able to complete the recommended intervention course. Counts represent number of subjects who developed a symptom that prevented the ability to complete the dose/study period.</description>
        <time_frame>1 (dose escalation groups) or 4 (maximally tolerated dose) weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation Group 1</title>
            <description>1 slice bread per day</description>
          </group>
          <group group_id="O2">
            <title>Dose Escalation Group 2</title>
            <description>2 slices per day</description>
          </group>
          <group group_id="O3">
            <title>Dose Escalation Group 3</title>
            <description>3 slices per day</description>
          </group>
          <group group_id="O4">
            <title>Maximally Tolerated Dose Group</title>
            <description>maximally tolerated dose (3 slices/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Limiting Toxicities</title>
          <description>Participants were evaluated for the development of bothersome symptoms that prevented them from being able to complete the recommended intervention course. Counts represent number of subjects who developed a symptom that prevented the ability to complete the dose/study period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pro-inflammatory Cytokines</title>
        <description>Changes in the serum were assessed for TNF-alpha prior to and following introduction of soy bread</description>
        <time_frame>1 (dose escalation group) or 4 weeks (maximally tolerated subject)</time_frame>
        <population>For the purposes of analyzing the secondary outcomes all subjects completing any of the dose escalation groups were combined.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Escalation (DE) Phase</title>
            <description>Data for each of the 3 doses were examined collectively.</description>
          </group>
          <group group_id="O2">
            <title>Maximum Tolerated Dose (MTD) Phase</title>
            <description>Actual data for subjects who completed MTD phase over 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pro-inflammatory Cytokines</title>
          <description>Changes in the serum were assessed for TNF-alpha prior to and following introduction of soy bread</description>
          <population>For the purposes of analyzing the secondary outcomes all subjects completing any of the dose escalation groups were combined.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 value of TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.72"/>
                    <measurement group_id="O2" value="7.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 value of TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.56"/>
                    <measurement group_id="O2" value="7.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Escalation Group 1</title>
          <description>1 slice per day</description>
        </group>
        <group group_id="E2">
          <title>Dose Escalation Group 2</title>
          <description>2 slices per day</description>
        </group>
        <group group_id="E3">
          <title>Dose Escalation Group 3</title>
          <description>3 slices per day</description>
        </group>
        <group group_id="E4">
          <title>Maximally Tolerated Dose</title>
          <description>an extended exposure to the maximally tolerated dose of 3 slices per day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Casey McClurkin</name_or_title>
      <organization>Ohio State University</organization>
      <phone>614-293-6255</phone>
      <email>casey.mclurkin@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

